Replimune Group (NASDAQ:REPL) Price Target Raised to $20.00

Дата публикации: 10-08-2026 05:48:48

Replimune Group (NASDAQ:REPL – Free Report) had its price objective increased by JPMorgan Chase & Co. from $17.00 to $20.00 in a research note published on Friday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock. REPL has been the topic of a number of other reports. Leerink Partners upgraded […]

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Royalty Pharma (NASDAQ:RPRX) Price Target Raised to $62.00	0	13.82	10-08-2026
2	Target (NYSE:TGT) Price Target Raised to $157.00	0	13.85	10-08-2026
3	PAR Technology (NYSE:PAR) Price Target Raised to $18.00	0	14.24	10-08-2026
4	Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $146.00	0	14.22	10-08-2026
5	Sotera Health (NASDAQ:SHC) Price Target Raised to $18.00	0	12.25	10-08-2026
6	JFrog (NASDAQ:FROG) Price Target Raised to $115.00	0	14.6	10-08-2026
7	Odyssey Therapeutics (NASDAQ:ODTX) Price Target Raised to $29.00	0	14.24	10-08-2026
8	Genpact (NYSE:G) Price Target Raised to $45.00	0	14.26	10-08-2026
9	Once Upon A Farm (NYSE:OFRM) Price Target Raised to $26.00	0	12.63	10-08-2026
10	Cadre (NYSE:CDRE) Price Target Raised to $45.00	0	13.85	10-08-2026

Классификация: Экономика. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 13.83. Источник: www.americanbankingnews.com.